GlobeNewswire: Editas Medicine, Inc. Contains the last 10 of 251 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:46:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/28/2836806/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2023-Results-and-Business-Updates.html?f=22&fvtc=4&fvtv=28193Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates2024-02-28T12:00:00Z<![CDATA[Company aligned with FDA that RUBY is a single Phase 1/2/3 trial]]>https://www.globenewswire.com/news-release/2024/02/21/2832602/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2023-Results-Conference-Call-and-Upcoming-Investor-Events.html?f=22&fvtc=4&fvtv=28193Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events2024-02-21T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update.]]>https://www.globenewswire.com/news-release/2024/01/31/2821218/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=28193Editas Medicine to Participate in Upcoming Investor Conferences2024-01-31T14:00:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:]]>https://www.globenewswire.com/news-release/2024/01/08/2805430/0/en/Editas-Medicine-Highlights-2024-Anticipated-Milestones-and-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=28193Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference2024-01-08T13:15:00Z<![CDATA[Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP]]>https://www.globenewswire.com/news-release/2024/01/03/2803160/0/en/Editas-Medicine-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=28193Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.]]>https://www.globenewswire.com/news-release/2023/12/13/2795602/0/en/Editas-Medicine-and-Vertex-Pharmaceuticals-Enter-into-Non-exclusive-License-Agreement-for-Cas9.html?f=22&fvtc=4&fvtv=28193Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas92023-12-13T14:00:00Z<![CDATA[Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel)]]>https://www.globenewswire.com/news-release/2023/12/11/2794110/0/en/Editas-Medicine-Announces-New-EDIT-301-Safety-and-Efficacy-Data-in-17-Patients-Presented-Today-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-and-in-a-Company-sponsored-W.html?f=22&fvtc=4&fvtv=28193Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar2023-12-11T17:00:00Z<![CDATA[All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%]]>https://www.globenewswire.com/news-release/2023/11/03/2773078/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-and-Business-Updates.html?f=22&fvtc=4&fvtv=28193Editas Medicine Announces Third Quarter 2023 Results and Business Updates2023-11-03T11:00:00Z<![CDATA[Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar]]>https://www.globenewswire.com/news-release/2023/11/02/2772452/0/en/Editas-Medicine-to-Present-Clinical-Data-from-the-RUBY-and-EdiTHAL-Trials-of-EDIT-301-at-the-ASH-2023-Annual-Meeting-and-in-a-Company-sponsored-Webinar.html?f=22&fvtc=4&fvtv=28193Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar2023-11-02T13:12:24Z<![CDATA[Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET]]>https://www.globenewswire.com/news-release/2023/10/27/2768274/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-Conference-Call-and-Upcoming-Investor-Events.html?f=22&fvtc=4&fvtv=28193Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events2023-10-27T11:00:00Z<![CDATA[CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update.]]>